Page last updated: 2024-09-05

sb 203580 and 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide

sb 203580 has been researched along with 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide in 3 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide)	Trials (4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide)	Recent Studies (post-2010) (4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide)
3,489	4	1,137	5	0	4

Protein Interaction Comparison

Protein	Taxonomy	sb 203580 (IC50)	4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide (IC50)
Mitogen-activated protein kinase 14	Mus musculus (house mouse)		0.33

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bachler, MA; Bagley, MC; Davis, T; Dix, MC; Kipling, D; Murziani, PG; Rokicki, MJ; Widdowson, CS; Zayed, JM	1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A	1
Munoz, L	1

Reviews

1 review(s) available for sb 203580 and 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide

Article	Year
Non-kinase targets of protein kinase inhibitors. Nature reviews. Drug discovery, 2017, Volume: 16, Issue:6 Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases	2017

Other Studies

2 other study(ies) available for sb 203580 and 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide

Article	Year
Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24 Topics: Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinase 14; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Substrate Specificity; Werner Syndrome	2007
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2 Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase	2013

Article

Year

Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.

Bioorganic & medicinal chemistry letters, 2007, Dec-15, Volume: 17, Issue:24

Topics: Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinase 14; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Substrate Specificity; Werner Syndrome

2007

A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013